ABVC Biopharma, Inc. — 10-Q Summary
Filing identity: The supplied filing is for American BriVision (Holding) Corporation, which describes a biotechnology business operating through American BriVision Corporation. It covers the three months ended March 31, 2018, with comparisons to the three months ended March 31, 2017. The company changed its fiscal year to the calendar year beginning January 1, 2018.
Business context and financial results
The company develops drug candidates and medical devices, aiming to advance products through proof-of-concept clinical trials and license them to pharmaceutical companies. Most products remained in development; the company reported no operating revenue in either comparative quarter.
| Metric | Q1 2018 | Q1 2017 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $226,545 | $236,841 |
| Research and development expense | $45,055 | $25,150 |
| Interest expense | $33,645 | $19,000 |
| Net loss | $262,040 | $256,671 |
| Basic and diluted loss per share | $(0.00) | $(0.00) |
| Cash used in operating activities | $137,657 | $862,235 |
With no revenue or cost of revenue, a gross margin is not meaningful. Operating expenses declined modestly overall, while R&D expense increased about 80%, which management attributed primarily to increased work on the vitreous substitute for vitrectomy project. Net loss was broadly stable; higher interest expense largely offset lower operating expenses.
Balance sheet, liquidity and financing
- At March 31, 2018, cash was $5,675, down from $93,332 at December 31, 2017.
- Current assets were $2,555,675, including a $2,550,000 receivable from a related collaboration partner. Current liabilities were $4,489,004, resulting in a $1,933,329 working-capital deficit.
- Total liabilities were $4,489,004, including $4,286,320 due to related parties and $202,684 of accrued expenses. The filing presents no separate total-debt figure.
- Operating cash outflow was $137,657; $50,000 of related-party borrowing provided financing. Cash declined by $87,657 during the quarter.
- Management stated that available funds were insufficient to operate for the next 12 months and that additional capital would be required. Potential sources include equity sales and borrowing; success is not assured, and equity financing could dilute shareholders.
Material changes, outlook and risks
- Related-party funding and collection risk: The company reported a $2,550,000 receivable related to the Rgene co-development agreement; it had received only $450,000 of the $3,000,000 amount and was still discussing payment timing. No licensing income or sales profit had occurred.
- Related-party obligations: Related-party balances included a $950,000 BioFirst loan bearing 12% annual interest, extended to February 1, 2019; a $160,000 AsianGene loan and a $50,000 YuanGene loan, each bearing 12% annual interest and due in January 2019; and other advances due on demand. The filing also describes a $3,000,000 BioFirst collaboration payment obligation. Its disclosures differ on whether a $300,000 upfront payment was made: the MD&A says it was paid, while the notes say no payment had been made as of the report date.
- Development commitments: The BioLite agreement covers six products and provides for payments of up to $100 million tied to milestones. The first Phase II trial was not complete as of March 31, 2018; a $15 million milestone is specified upon its completion. These are contractual milestone amounts, not reported current-period expenses.
- Going concern: The company reported a $16,038,638 accumulated deficit and a $262,040 quarterly net loss. It warned that continuation depends on obtaining financing and achieving profitable operations, with no assurance that its plans will succeed.
- Controls and governance: Management concluded disclosure controls and procedures were not effective as of March 31, 2018. It reported no material changes in internal control over financial reporting during the quarter. The filing disclosed a January 31, 2018 merger agreement involving BioLite Holding and BioKey; completion was not established in the supplied filing.
- Other items: The company issued shares for consulting, listing-related services and officer salaries. No legal proceedings or material off-balance-sheet arrangements were reported. Management provided no quantified revenue or earnings guidance.
Investor verification priorities
- Verify the collectability and timing of the $2.55 million Rgene-related receivable, and whether any amounts have since been received.
- Reconcile the BioFirst disclosure on the $300,000 upfront payment and confirm the outstanding collaboration obligation and related-party balances.
- Assess near-term liquidity, financing availability, related-party loan maturities and the company’s going-concern position.
- Check the status and terms of the proposed BioLite Holding/BioKey merger and any resulting share issuance or dilution.
- Review remediation of the ineffective disclosure controls and the progress, costs and milestone status of the clinical programs.